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Background
Recent technological advances in DNA sequencing have
yielded more comprehensive identification of mutations
occurring in tumors. These efforts have detected recurrent
mutations in a gene encoding isocitrate dehydrogenase
(IDH1) in several tumor types including prostate cancer.
In each of these tumors IDH1 missense mutations at argi-
nine 132 (R132) confer a gain of function and produce an
aberrant metabolite, 2-hydroxyglutarate (2HG) as opposed
to wild type (WT) activity that produces alpha-ketogluta-
rate (a-KG). a-KG is a cofactor for the Ten-Eleven Trans-
location enzymes (TET1/2/3), which catalyze DNA
hydroxymethylation. Although this DNA modification is
predicted to affect epigenetic regulation, its specific effects
and target genes remain unclear. We hypothesize that
2HG produced by mutant IDH1 promotes tumor pheno-
types through mechanisms directly affecting DNA
hydroxymethylation.
Materials and methods
We tested our hypothesis in a cell culture model using
RWPE cells, which were derived from a histologically nor-
mal adult human prostate. These cells were infected with
retrovirus co-expressing green fluorescent protein together
with either WT or R132H alleles of IDH1. 2HG levels
were quantified by a fluorometric assay that measures
NADH produced by 2HG-dehydrogenase. DNA hydroxy-
methylation was measured in genomic DNA samples by
dot blots with immunodetection using a rabbit polyclonal
antibody (Active Motif #39770). Gene expression was
measured by quantitative-PCR on cDNA prepared from
total RNA isolations. Cell proliferation was evaluated by
measuring cellular conversion of methylthiazolyldiphenyl-
tetrazolium (MTT) to purple-colored formazan that is
quantified by measuring absorbance at l = 600 nm.
Results
RWPE cells expressing the R132H mutant produced 2HG
at levels comparable to those measured in cancer cell lines
with endogenous IDH1 mutations, whereas 2HG was not
generated by IDH1 WT overexpression. Relative to WT-
expressing or uninfected cells we observed that global
DNA hydroxymethylation was reduced in R132H-expres-
sing cells. Moreover, our data suggest that this trend
increases with duration of R132H expression. Reduced
DNA hydroxymethylation likely results from inhibition of
TET2 and/or TET3, because TET1 expression was not
detected in RWPE cells. Despite molecular changes asso-
ciated with IDH1 R132H expression, proliferation was not
affected when cells were cultured in complete media.
However, 2HG conferred a growth advantage to RWPE
cells cultured with reduced growth factor levels.
Conclusions
Production of 2HG by mutant IDH1 expression was suf-
ficient to reduce global levels of DNA hydroxymethyla-
tion in prostate epithelial cells. Moreover, these cells
exhibited increased proliferation upon 2HG exposure
when cultured in media with diminished growth factors,
which is intended to better mimic resource limitations
of tumor growth. Collectively these findings improve
our understanding of how IDH1 mutations promote
carcinogenesis with the goal of developing effective tar-
geted therapies against IDH1 mutant tumors.
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